Social Europe

politics, economy and employment & labour

  • Projects
    • Corporate Taxation in a Globalised Era
    • US Election 2020
    • The Transformation of Work
    • The Coronavirus Crisis and the Welfare State
    • Just Transition
    • Artificial intelligence, work and society
    • What is inequality?
    • Europe 2025
    • The Crisis Of Globalisation
  • Audiovisual
    • Audio Podcast
    • Video Podcasts
    • Social Europe Talk Videos
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Shop
  • Membership
  • Ads
  • Newsletter

What when there’s a vaccine?

by Stuart Blume and Maurizia Mezza on 15th May 2020

Share on TwitterShare on FacebookShare on LinkedIn

Amid the accelerated scientific quest for a vaccine against the coronavirus, crucial ethical and social questions have not yet been addressed.

vaccine
Stuart Blume

Each day brings reports of progress toward a coronavirus vaccine. As millions struggle with separation, loss of income, isolation and fear for vulnerable loved ones, the prospect of a vaccine offers courage and hope.

Vaccination has indeed saved countless lives and has been a cornerstone of public health for more than half a century. Currently 120 candidate vaccines against the coronavirus are under development, of which eight have entered human trials. One or more will almost certainly become available—not this year, hopefully next. But what then?

vaccine
Maurizia Mezza

How the vaccine is to be deployed may seem a trivial question compared with the urgency of today. Just a few months ago the only vaccination-related concern seemed to be the reluctance of some parents to have their child vaccinated.

Nevertheless, the history of recent vaccination campaigns shows that introducing a new vaccine is rarely unproblematic. It is best to clarify potential problems before solving them becomes itself a matter of urgency.

Two scenarios

When a vaccine is licensed, what are these problems likely to be? Over the months to come we can imagine two scenarios.

Join our growing community newsletter!

"Social Europe publishes thought-provoking articles on the big political and economic issues of our time analysed from a European viewpoint. Indispensable reading!"

Polly Toynbee

Columnist for The Guardian

Thank you very much for your interest! Now please check your email to confirm your subscription.

There was an error submitting your subscription. Please try again.

Powered by ConvertKit

In the first, optimistic, scenario, a combination of hygienic, social and therapeutic measures will have brought the epidemic under control. There will be no dreaded ‘second wave’. When the vaccine becomes available, people will view Covid-19 as akin to the flu. In Europe, rates of vaccination against seasonal influenza among over-65s vary hugely between countries: from less than 20 per cent to nearly 80 per cent.

When the human papilloma virus (HPV) vaccine was introduced, not only were initial vaccination rates lower than expected but here too huge differences emerged between countries. In Scotland in 2012 86.4 per cent of the target population (of adolescent girls) were vaccinated, but in Greece only 9 per cent. This was partly explicable in terms of how vaccination was organised—school-based programmes achieved higher rates. But sometimes girls were cajoled, threatened or bullied into getting themselves vaccinated.

Will it matter if there is little demand for the vaccine? The answer depends on the coverage needed for ‘herd immunity’. If enough people are immune, whether from vaccination or recovery, circulation of the virus is restricted. Unvaccinated people are then protected. The threshold percentage varies from one virus to another and may be around 70 per cent for the SARS-CoV-2 virus. It does matter.

Reports of responses to current social-distancing rules give some idea of the groups in which coverage might be problematically low: young people who regard themselves as low-risk, whole regions in which the state is viewed with suspicion and communities cut off by language or detained in overcrowded refugee camps. If adequate coverage is not achieved, what then? What measure of compulsion is acceptable?


We need your help! Please join our mission to improve public policy debates.


As you may know, Social Europe is an independent publisher. We aren't backed by a large publishing house or big advertising partners. For the longevity of Social Europe we depend on our loyal readers - we depend on you. You can support us by becoming a Social Europe member for less than 5 Euro per month.

Thank you very much for your support!

Become a Social Europe Member

Supply outstripped

In a second scenario the epidemic will have re-emerged. People are again dying. Everyone is clamouring to be vaccinated.

But the new vaccine is expensive and there is too little of it. Most of the institutions with vaccines already in human trials are small biotech firms. Production will gear up gradually and for months international demand will outstrip supply. Poor countries with weak health systems will be pushed to the back of the queue—however great their need.

This is what happened with HPV vaccines when they first became available in 2006. Four-fifths of the women affected by an HPV-related disease live in low and middle-income countries. But at $360 per capita for the required three shots these countries could not afford the vaccines at the time.

The introduction of the H1N1 flu vaccine in 2009 is also illuminating. When H1N1 was declared a pandemic, advance purchase contracts were automatically activated. Wealthy countries had paid an annual subscription to maintain these, sometimes with more than one manufacturer. They then had prior claim on a limited supply, though still only part of what they had ordered. Many countries subsequently developed guidelines, anticipating a future influenza pandemic.

Under such guidelines, priority should be given to healthcare workers and to people at greatest medical risk—as in respect of the coronavirus epidemic. But where regional sentiments are strong the most affected regions might claim priority or, elsewhere, insist that supplies should be equitably distributed among regions.

What has to be avoided at all costs is the nationalistic pushing and shoving which has taken place in recent weeks over ventilators and diagnostic tests. Can acceptable rationing criteria be found, so political haggling is later avoided?

Contract secrecy

Experience with the H1N1 vaccine a decade ago highlights something else. Although not public knowledge at the time, it emerged that many contracts absolved manufacturers of any obligation in respect of vaccine-related complications or side-effects. And such complications did arise: in Sweden and Finland, for example, cases of narcolepsy were found to be associated with one of the influenza vaccines used to control the pandemic.

Three of the eight candidate vaccines now in human trials make use of genetic material from the virus. The underlying technology has never been proven in a licensed human vaccine. There will be pressure to fast-track a coronavirus vaccine. Since there will not have been time to test it in all population groups, side-effects might again emerge.

An acceptable division of responsibility between states and manufacturers in the event of this happening needs to be established. Can the European Union use its bargaining power to negotiate contracts on behalf of member states, while not forgetting the interests of poor member (and non-member) countries?

None of this is to cast the slightest doubt on the crucial value of a coronavirus vaccine. But whatever our hopes, the licensing of a safe and effective vaccine will still leave difficult issues of accessibility, acceptability and responsibility—which need to be debated.

An earlier version of this article appeared in Italian in Il Manifesto

Share on TwitterShare on FacebookShare on LinkedIn
Home ・ What when there’s a vaccine?

Filed Under: Politics Tagged With: coronavirus

About Stuart Blume and Maurizia Mezza

Stuart Blume is emeritus professor of science and technology studies at the University of Amsterdam and author of Immunization: How Vaccines Became Controversial (Reaktion Books, 2017). Maurizia Mezza is a doctoral candidate in medical anthropology at the University of Amsterdam, focusing on epidemiological studies and pharmacovigilance in relation to HPV vaccination.

Partner Ads

Most Popular Posts

Thomas Piketty,capital Capital and ideology: interview with Thomas Piketty Thomas Piketty
sovereignty Brexit and the misunderstanding of sovereignty Peter Verovšek
China,cold war The first global event in the history of humankind Branko Milanovic
centre-left, Democratic Party The Biden victory and the future of the centre-left EJ Dionne Jr
Covid 19 vaccine Designing vaccines for people, not profits Mariana Mazzucato, Henry Lishi Li and Els Torreele

Most Recent Posts

Uber,drivers,gig UK gig drivers recognised as workers—what next? Jill Toh
women workers,services Covid-19: a tale of two service sectors John Hurley
European Pillar of Social Rights,social pillar EU credibility as a people’s union rests on the social pillar Liina Carr
vaccine nationalism,Big Pharma Vaccine nationalism won’t defeat the pandemic Sharan Burrow
Can we change the climate on climate change? Karin Pettersson

Other Social Europe Publications

US election 2020
Corporate taxation in a globalised era
The transformation of work
The coronavirus crisis and the welfare state
Whither Social Rights in (Post-)Brexit Europe?

Social Europe Publishing book

With a pandemic raging, for those countries most affected by Brexit the end of the transition could not come at a worse time. Yet, might the UK's withdrawal be a blessing in disguise? With its biggest veto player gone, might the European Pillar of Social Rights take centre stage? This book brings together leading experts in European politics and policy to examine social citizenship rights across the European continent in the wake of Brexit. Will member states see an enhanced social Europe or a race to the bottom?

'This book correctly emphasises the need to place the future of social rights in Europe front and centre in the post-Brexit debate, to move on from the economistic bias that has obscured our vision of a progressive social Europe.' Michael D Higgins, president of Ireland


MORE INFO

Hans Böckler Stiftung Advertisement

Renewing labour relations in the German meat industry: an end to 'organised irresponsibility'?

Over the course of 2020, repeated outbreaks of Covid-19 in a number of large German meat-processing plants led to renewed public concern about the longstanding labour abuses in this industry. New legislation providing for enhanced inspection on health and safety, together with a ban on contract work and limitations on the use of temporary agency employees, holds out the prospect of a profound change in employment practices and labour relations in the meat industry. Changes in the law are not sufficient, on their own, to ensure decent working conditions, however. There is also a need to re-establish the previously high level of collective-bargaining coverage in the industry, underpinned by an industry-wide collective agreement extended by law to cover the entire sector.


FREE DOWNLOAD

ETUI advertisement

ETUI/ETUC (online) conference Towards a new socio-ecological contract 3-5 February 2021

The need to effectively tackle global warming puts under pressure the existing industrial relations models in Europe. A viable world of labour requires a new sustainability paradigm: economic, social and environmental.

The required paradigm shift implies large-scale economic and societal change and serious deliberation. All workers need to be actively involved and nobody should be left behind. Massive societal coalitions will have to be built for a shared vision to emerge and for a just transition, with fairly distributed costs, to be supported. But this is also an opportunity to redefine our societal goals and how they relate to the current focus on (green) growth.


REPLAY ALL SESSIONS

To access the videos, click on the chosen day then click on the ‘video’ button of your chosen session (plenary or panel). It will bring you immediately to the corresponding video. To access the available presentations, click on the chosen day then click on the ‘information’ button. Check the links to the available presentations.

Eurofound advertisement

Industrial relations: developments 2015-2019

Eurofound has monitored and analysed developments in industrial relations systems at EU level and in EU member states for over 40 years. This new flagship report provides an overview of developments in industrial relations and social dialogue in the years immediately prior to the Covid-19 outbreak. Findings are placed in the context of the key developments in EU policy affecting employment, working conditions and social policy, and linked to the work done by social partners—as well as public authorities—at European and national levels.


CLICK FOR MORE INFO

Foundation for European Progressive Studies Advertisement

FEPS Progressive Yearbook

Twenty-twenty has been an extraordinary year. The Covid-19 pandemic and the multidimensional crisis that it triggered have boosted existing trends and put forward new challenges. But they have also created unexpected opportunities to set a new course of action for the European Union and—hopefully—make a remarkable leap forward in European integration.

The second edition of the Progressive Yearbook, the yearly publication of the Foundation for European Progressive studies, revolves around the exceptional events of 2020 and looks at the social, economic and political impact they will have in 2021. It is a unique publication, which aims to be an instrument for the progressive family to reflect on the recent past and look ahead to our next future.


CLICK HERE

About Social Europe

Our Mission

Article Submission

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Find Social Europe Content

Search Social Europe

Project Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

.EU Web Awards